Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ondřej Kyselák"'
Autor:
Ondřej Kyselák, Vladimír Soška
Publikováno v:
Vnitrni lekarstvi. 67(3)
In many patients it is difficult to achieve the current very low target LDL-cholesterol levels, recommended for the prevention of atherosclerotic cardiovascular events. If statin therapy or statins in combination with ezetimibe are not sufficient, ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc70a6e8e117caa9d8e5a1bb247fae5
https://pubmed.ncbi.nlm.nih.gov/34171952
https://pubmed.ncbi.nlm.nih.gov/34171952
Autor:
Vladimír Soška, Ondřej Kyselák
Publikováno v:
Vnitřní lékařství. 63:663-666
Statins are key drugs for patients in secondary prevention of cardiovascular disease, as well as for primary prevention patients at high or very high risk of fatal cardiovascular events. However, long-term compliance of patients to statin therapy is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542c2c619e8116e0d48c652f57ecc21b
https://doi.org/10.36290/vnl.2017.129
https://doi.org/10.36290/vnl.2017.129
Autor:
Ondřej Kyselák, Vladimír Soška
Publikováno v:
Vnitrni lekarstvi. 64(10)
Statins are among the most important drugs in preventive cardiology because they greatly improve the prognosis of risk patients in both primary and secondary prevention of atherosclerotic cardiovascular disease. Adherence to long-term statin therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a40c1c35f92596f55640b9b2c7f0ab
https://pubmed.ncbi.nlm.nih.gov/30590938
https://pubmed.ncbi.nlm.nih.gov/30590938
Autor:
Ondřej Kyselák, Vladimír Soška
Publikováno v:
Atherosclerosis. 287:e219-e220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4458373fb7c8b2eb5f7ec637252552a
https://doi.org/10.1016/j.atherosclerosis.2019.06.670
https://doi.org/10.1016/j.atherosclerosis.2019.06.670
Autor:
Vladimír Soška, Ondřej Kyselák
Publikováno v:
Interní medicína pro praxi. 18:6-8
Zakladnimi leky ke sniženi LDL-cholesterolu jsou statiny: ty maji nejvice důkazů o tom, že snižuji jak LDL-cholesterol, tak i kardiovaskularni přihody a mortalitu. Lekem druhe volby ke sniženi LDL-cholesterolu (do kombinace se statiny) je ezet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18d24eb855efa595da90407491992a66
https://doi.org/10.36290/int.2016.002
https://doi.org/10.36290/int.2016.002
Autor:
Soska, S Zemek, Robin Urbanek, Tomáš Freiberger, J. Dvor̆áková, Blaha, R. Češka, Ondřej Kyselák, B Nussbaumerova, Martina Vaclová, Michal Vrablík, S Tesarova, J. Hyanek, Pavel Horák, P. Vyroubal, L. Zlatohlavek, Helena Vaverkova
Publikováno v:
Atherosclerosis. 275:e178
Aim: Aim of project was to define general characteristics of patients with homozygous form of familial hypercholesterolaemia in the Czech Republic. Methods: Set of hoFH patients has 19 patients, including 5 ceased. Patients were selected by the genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9f18fcd64f343267eaf93531f5df82
https://doi.org/10.1016/j.atherosclerosis.2018.06.541
https://doi.org/10.1016/j.atherosclerosis.2018.06.541
Autor:
Vladimír Soška, Ondřej Kyselák
Publikováno v:
Atherosclerosis. 275:e182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d8343612b8d18f13507c77428e94b2a
https://doi.org/10.1016/j.atherosclerosis.2018.06.555
https://doi.org/10.1016/j.atherosclerosis.2018.06.555